Age-related increases in IGFBP2 increase melanoma cell invasion and lipid synthesis

Aged melanoma patients (>65 years old) have more aggressive disease relative to young patients (<55 years old) for reasons that are not completely understood. Analysis of the young and aged secretome from human dermal fibroblasts identified >5-fold levels of insulin-like growth factor binding protein 2 (IGFBP2) in the aged fibroblast secretome. IGFBP2 functionally triggers upregulation of the PI3K-dependent fatty acid biosynthesis program in melanoma cells through increases in FASN. Melanoma cells co-cultured with aged dermal fibroblasts have higher levels of lipids relative to young dermal fibroblasts, which can be lowered by silencing IGFBP2 expression in fibroblasts, prior to treating with conditioned media. Conversely, ectopically treating melanoma cells with recombinant IGFBP2 in the presence of conditioned media from young fibroblasts, promoted lipid synthesis and accumulation in the melanoma cells. Neutralizing IGFBP2 in vitro reduces migration and invasion in melanoma cells, and in vivo studies demonstrate that neutralizing IGFBP2 in syngeneic aged mice, ablates tumor growth as well as metastasis. Conversely, ectopic treatment of young mice with IGFBP2 in young mice increases tumor growth and metastasis. Our data reveal that aged dermal fibroblasts increase melanoma cell aggressiveness through increased secretion of IGFBP2, stressing the importance of considering age when designing studies and treatment. Significance The aged microenvironment drives metastasis in melanoma cells. This study reports that IGFBP2 secretion by aged fibroblasts induces FASN in melanoma cells and drives metastasis. Neutralizing IGFBP2 decreases melanoma tumor growth and metastasis.

[1]  L. Cope,et al.  Spatial transcriptomic analysis of ovarian cancer precursors reveals reactivation of IGFBP2 during pathogenesis. , 2022, Cancer research.

[2]  T. Dandekar,et al.  Progeria and Aging—Omics Based Comparative Analysis , 2022, Biomedicines.

[3]  Stephen M. Douglass,et al.  Stromal changes in the aged lung induce an emergence from melanoma dormancy , 2020, Nature.

[4]  G. Bergers,et al.  The metabolism of cancer cells during metastasis , 2021, Nature Reviews Cancer.

[5]  Hua Li,et al.  Fatty acid synthase promotes breast cancer metastasis by mediating changes in fatty acid metabolism , 2020, Oncology letters.

[6]  T. Graeber,et al.  Melanoma dedifferentiation induced by IFN- γ epigenetic remodeling in response to anti–PD-1 therapy , 2021 .

[7]  Lai-Feng Wei,et al.  IGFBP2 in cancer: Pathological role and clinical significance (Review). , 2020, Oncology reports.

[8]  R. de Cabo,et al.  Age-induced accumulation of methylmalonic acid promotes tumour progression , 2020, Nature.

[9]  J. Oxley,et al.  IGF-1 and hyperglycaemia-induced FOXA1 and IGFBP-2 affect epithelial to mesenchymal transition in prostate epithelial cells , 2020, Oncotarget.

[10]  Stephen M. Douglass,et al.  Changes in Aged Fibroblast Lipid Metabolism Induce Age-dependent Melanoma Cell Resistance to Targeted Therapy Via the Fatty Acid Transporter FATP2. , 2020, Cancer discovery.

[11]  E. Dellambra,et al.  Intracellular Insulin-like growth factor binding protein 2 (IGFBP2) contributes to the senescence of keratinocytes in psoriasis by stabilizing cytoplasmic p21 , 2020, Aging.

[12]  Wei Zhang,et al.  IGFBP2 regulates PD-L1 expression by activating the EGFR-STAT3 signaling pathway in malignant melanoma. , 2020, Cancer letters.

[13]  G. Fuller,et al.  IGFBP2: integrative hub of developmental and oncogenic signaling network , 2020, Oncogene.

[14]  Ming-Rong Wang,et al.  Overexpression of IGFBP2 mRNA predicts poor survival in patients with glioblastoma , 2019, Bioscience reports.

[15]  L. Ferrucci,et al.  IGFBP-2 and aging: a 20-year longitudinal study on IGFBP-2, IGF-I, BMI, insulin sensitivity and mortality in an aging population. , 2019, European journal of endocrinology.

[16]  E. Lengyel,et al.  Fibroblasts Mobilize Tumor Cell Glycogen to Promote Proliferation and Metastasis. , 2019, Cell metabolism.

[17]  M. Schulze,et al.  Insulin-Like Growth Factor Binding Protein 2 (IGFBP-2) and the Risk of Developing Type 2 Diabetes , 2018, Diabetes.

[18]  A. Hauschild,et al.  Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600–Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials , 2018, JAMA oncology.

[19]  Avi Ma’ayan,et al.  SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signalling , 2018, Nature Communications.

[20]  R. White,et al.  Adipocyte-Derived Lipids Mediate Melanoma Progression via FATP Proteins. , 2018, Cancer discovery.

[21]  Deliang Guo,et al.  Lipid metabolism reprogramming and its potential targets in cancer , 2018, Cancer communications.

[22]  M. Bosenberg,et al.  Genetics of metastasis: melanoma and other cancers , 2018, Clinical & Experimental Metastasis.

[23]  G. Mills,et al.  A Unified Approach to Targeting the Lysosome's Degradative and Growth Signaling Roles. , 2017, Cancer discovery.

[24]  A. Weeraratna,et al.  Inhibition of Age-Related Therapy Resistance in Melanoma by Rosiglitazone-Mediated Induction of Klotho , 2017, Clinical Cancer Research.

[25]  Camille Stephan-Otto Attolini,et al.  Targeting metastasis-initiating cells through the fatty acid receptor CD36 , 2016, Nature.

[26]  G. Fuller,et al.  Glioma progression is mediated by an addiction to aberrant IGFBP2 expression and can be blocked using anti‐IGFBP2 strategies , 2016, The Journal of pathology.

[27]  M. Platzer,et al.  Conserved Senescence Associated Genes and Pathways in Primary Human Fibroblasts Detected by RNA-Seq , 2016, PloS one.

[28]  L. Ferrucci,et al.  sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance , 2016, Nature.

[29]  S. Beloribi-Djefaflia,et al.  Lipid metabolic reprogramming in cancer cells , 2016, Oncogenesis.

[30]  A. Harris,et al.  Acetyl-CoA Synthetase 2 Promotes Acetate Utilization and Maintains Cancer Cell Growth under Metabolic Stress , 2015, Cancer cell.

[31]  G. E. Atilla‐Gokcumen,et al.  Lipids in cell biology: how can we understand them better? , 2014, Molecular biology of the cell.

[32]  A. Schulze,et al.  Hooked on fat: the role of lipid synthesis in cancer metabolism and tumour development , 2013, Disease Models & Mechanisms.

[33]  Manuel Serrano,et al.  The Hallmarks of Aging , 2013, Cell.

[34]  Jun S. Song,et al.  Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF. , 2013, Cancer cell.

[35]  J. Campisi,et al.  Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. , 2013, The Journal of clinical investigation.

[36]  A. Harris,et al.  Sterol regulatory element binding protein-dependent regulation of lipid synthesis supports cell survival and tumor growth , 2013, Cancer & Metabolism.

[37]  M. Herlyn,et al.  The Three-Dimensional Human Skin Reconstruct Model: a Tool to Study Normal Skin and Melanoma Progression , 2011, Journal of visualized experiments : JoVE.

[38]  D. Gillatt,et al.  Insulin-like growth factor-binding protein-2 promotes prostate cancer cell growth via IGF-dependent or -independent mechanisms and reduces the efficacy of docetaxel , 2011, British Journal of Cancer.

[39]  Yuan Tian,et al.  Expression of Fatty Acid Synthase Depends on NAC1 and Is Associated with Recurrent Ovarian Serous Carcinomas , 2010, Journal of oncology.

[40]  Judith Campisi,et al.  Senescent cells as a source of inflammatory factors for tumor progression , 2010, Cancer and Metastasis Reviews.

[41]  R. Wysocki,et al.  Antidiabetic effects of IGFBP2, a leptin-regulated gene. , 2010, Cell metabolism.

[42]  P. Fortina,et al.  The reverse Warburg effect: Aerobic glycolysis in cancer associated fibroblasts and the tumor stroma , 2009, Cell cycle.

[43]  Shuhei Yoshida,et al.  Lipid rafts and caveolin-1 are required for invadopodia formation and extracellular matrix degradation by human breast cancer cells. , 2009, Cancer research.

[44]  S. Horvath,et al.  Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer , 2007, Proceedings of the National Academy of Sciences.

[45]  S. Plymate,et al.  Characterization of insulin-like growth factor-binding protein-related proteins (IGFBP-rPs) 1, 2, and 3 in human prostate epithelial cells: potential roles for IGFBP-rP1 and 2 in senescence of the prostatic epithelium. , 2000, Endocrinology.

[46]  T. Rohan,et al.  Role of the insulin-like growth factor family in cancer development and progression. , 2000, Journal of the National Cancer Institute.